CLINICAL TRIALS PROFILE FOR PF-07304814
✉ Email this page to a colleague
Clinical Trials for PF-07304814
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT04501978 ↗ | ACTIV-3: Therapeutics for Inpatients With COVID-19 | Recruiting | AIDS Clinical Trials Group | Phase 3 | This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either a study drug plus current standard of care (SOC), or with placebo plus current SOC. |
| NCT04501978 ↗ | ACTIV-3: Therapeutics for Inpatients With COVID-19 | Recruiting | AstraZeneca | Phase 3 | This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either a study drug plus current standard of care (SOC), or with placebo plus current SOC. |
| NCT04501978 ↗ | ACTIV-3: Therapeutics for Inpatients With COVID-19 | Recruiting | Brii Biosciences Limited | Phase 3 | This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either a study drug plus current standard of care (SOC), or with placebo plus current SOC. |
| NCT04501978 ↗ | ACTIV-3: Therapeutics for Inpatients With COVID-19 | Recruiting | Cardiothoracic Surgical Trials Network (CTSN) | Phase 3 | This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either a study drug plus current standard of care (SOC), or with placebo plus current SOC. |
| NCT04501978 ↗ | ACTIV-3: Therapeutics for Inpatients With COVID-19 | Recruiting | Eli Lilly and Company | Phase 3 | This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either a study drug plus current standard of care (SOC), or with placebo plus current SOC. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for PF-07304814
Condition Name
Clinical Trial Locations for PF-07304814
Trials by Country
Clinical Trial Progress for PF-07304814
Clinical Trial Phase
Clinical Trial Sponsors for PF-07304814
Sponsor Name
